Carlos Vicente-Jimenez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Outcomes of Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis in Myelodysplastic Syndromes: A Multicenter Study Conducted on Behalf of GETH-TC.

Outcomes of Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis in Myelodysplastic Syndromes: A Multicenter Study Conducted on Behalf of GETH-TC.

Journal: Transplantation and cellular therapy

Published: February 13, 2026

Outcomes of Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis in Myelodysplastic Syndromes: A Multicenter Study Conducted on Behalf of GETH-TC.

Outcomes of Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis in Myelodysplastic Syndromes: A Multicenter Study Conducted on Behalf of GETH-TC.

Journal: Transplantation and cellular therapy

Published: February 13, 2026

Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.

Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.

Journal: Annals of hematology

Published: April 09, 2025

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Journal: Blood cancer journal

Published: February 11, 2025

Rectal colonization by multidrug-resistant Gram-negative bacteria and subsequent bacteraemia in haematological patients.

Rectal colonization by multidrug-resistant Gram-negative bacteria and subsequent bacteraemia in haematological patients.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: January 14, 2025

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Journal: Experimental hematology & oncology

Published: December 26, 2024

Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC).

Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC).

Journal: Blood cancer journal

Published: November 05, 2024

At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens.

At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens.

Journal: Cancers

Published: November 04, 2024

Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics.

Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics.

Journal: British journal of haematology

Published: September 18, 2024

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia.

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia.

Journal: Haematologica

Published: September 07, 2024

Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.

Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.

Journal: International journal of molecular sciences

Published: June 17, 2024

Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study.

Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study.

Journal: Annals of hematology

Published: May 31, 2024

Showing 1-12 of 24

Last Updated: 09/26/2026